Active, not recruitingPhase 4NCT05942222
A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
Studying Secondary hypereosinophilic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rigshospitalet, Denmark
- Principal Investigator
- Christian Pedersen, MDDepartment of ORL, Head and Neck Surgery & Audiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Intervention
- dupilumab(biological)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (9)
- Aalborg Universitetssygehus Syd, Aalborg, Denmark
- Aarhus Universitetshospital Skejby, Aarhus, Denmark
- Rigshospitalet, Copenhagen, Denmark
- Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark
- Regionshospitalet Gødstrup, Herning, Denmark
- Nordsjællands Hospital, Hillerød, Denmark
- Sjællands Universitetshospital Køge, Køge, Denmark
- Odense Universitetshospital, Odense, Denmark
- Sygehus Lillebælt Vejle, Vejle, Denmark
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05942222 on ClinicalTrials.gov